<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222922</url>
  </required_header>
  <id_info>
    <org_study_id>B7661001</org_study_id>
    <secondary_id>2014-003296-36</secondary_id>
    <nct_id>NCT02222922</nct_id>
  </id_info>
  <brief_title>A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients
      with advanced solid tumors in order to determine the maximum tolerated dose and select the
      recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2014</start_date>
  <completion_date type="Actual">November 5, 2019</completion_date>
  <primary_completion_date type="Actual">November 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) {Part1}</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
    <description>First cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Q2W participants with Dose-limiting toxicities (DLT) {Part1}</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>First cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Days 1, 15, 21, and every 21 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-PF-06647020 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 1)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of response rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 2)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of overall response rate (ORR) and progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Days 1, 15, 28, and every 28 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-PF-06647020 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Q2W participants with objective response (single agent)</measure>
    <time_frame>Baseline, every 8 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of response rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of combination participants with objective response (PF-06647020 + avelumab)</measure>
    <time_frame>Baseline, every 8 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of overall response rate (ORR) and progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (avelumab)</measure>
    <time_frame>Days 1, 15, 28, and every 28 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-avelumab antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-06647020 Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug infused over 60 minutes once every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-drug interaction (DDI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06647020 combined with fluconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06647020 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug infused over 60 minutes once every 14 days (28 day cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06647020 combined with Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06647020 combined with Avelumab administered by infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 Q3W</intervention_name>
    <description>Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.
Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.</description>
    <arm_group_label>PF-06647020 Q3W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>combination drug used for drug-drug interaction sub-study</description>
    <arm_group_label>Drug-drug interaction (DDI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 Q2W</intervention_name>
    <description>Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.
Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.</description>
    <arm_group_label>PF-06647020 Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 combined with Avelumab</intervention_name>
    <description>Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.</description>
    <arm_group_label>PF-06647020 combined with Avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Q2W Inclusion Criteria:

          -  Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
             lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

          -  Performance Status of 0, 1, or 2

          -  Adequate bone marrow, kidney, and liver function

        Q2W Exclusion Criteria:

          -  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
             mullerian tumors, unresolved bowel obstruction

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start

          -  Active and clinically significant bacterial, fungal, or viral infection

        Q3W Inclusion Criteria:

          -  Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
             or for whom no standard therapy is available

          -  Performance Status of 0 or 1

          -  Adequate bone marrow, kidney, and liver function

          -  Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
             non small cell lung cancer patients

        Q3W Exclusion Criteria:

          -  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
             mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
             unresolved bowel obstruction

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start

          -  Active and clinically significant bacterial, fungal, or viral infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals DBA HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital Woodburn GYN Infusion Center</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA)</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Radiological Consultants</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Loudon Hospital</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7661001&amp;StudyName=A%20Study%20Of%20PF-06647020%20For%20Adult%20Patients%20With%20Advanced%20Solid%20Tumors%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADC</keyword>
  <keyword>PF-06647020</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>TNBC</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>advanced metastatic breast cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>OVCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

